“Cancer treatment keeps getting more targeted, and the market keeps getting bigger because of it.”

As genomic profiling becomes standard practice before treatment selection, precision oncology is absorbing share from broader chemotherapy approaches. This is one of the largest dollar figures in this batch for exactly that reason.